Use of intensive chemotherapy regiments in oncology and in bone marrow/progenitor cell transplantation programs has increased the demand for platelet products, particularly in patients with severe thrombocytopenia or bleeding complications. Use of apheresis platelet transfusions has also increased substantially, from 365,000 units in 1989 to 1,264,000 units in 2001 (Table 1) (1-3). This increase is being driven partly by the need for alternative platelet inventories to support cardiac surgery, oncology, and peripheral blood progenitor cell (PBPC) transplantation programs and partly by use of leukoreduced platelet products (4).

Emerging issues are renewing interest in platelet transfusion practices (5). This review discusses the current risks associated with platelet transfusion and emerging issues in platelet transfusion therapy, including re-evaluation of the platelet threshold for prophylactic transfusion and modification of platelet transfusion dose, as well as the role of hematopoietic growth factors in platelet recovery.

0 0

Post a comment